GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

GSK offers a robust dividend yield, but that's not the only thing to consider.

Is GSK an Excellent Dividend Stock to Buy for Passive Income Investors?

Galera Therapeutics

Kodiak Sciences Inc

We look at a few biotech companies, LEGN, KOD, GRTX, which are poised to beat second-quarter earnings estimates.

3 Biotech Stocks Poised to Beat Q2 Earnings Estimates

AbbVie

Moderna

With pharmaceutical companies, it's all about the pipeline of new medications. Drugmakers, and their pharma stocks, are judged based on sales of current medications and potential sales of future prescriptions.

3 Pharma Stocks to Sell in August Before They Crash and Burn

Broadstone Net Lease

Bank of Nova Scotia

BRT Apartments

Cardinal Health

Chimera Investment

Canadian Imperial Bank of Commerce

Cisco Systems

Eastman Chemical

Gap Inc

Iron Mountain

Illinois Tool Works

Coca-Cola

Leggett & Platt

Medtronic

MDU Resources Group

Medical Properties Trust

NetApp

Realty Income Corp

Orion Office REIT

Oracle

Paramount Global

Philip Morris

J. M. Smucker

In July, we received a dividend income total of $1,421.13. The $200 dividend from Canada Imperial was reinvested and acquired almost 5 more shares, adding more income. July was probably one of the lowest number of stocks increasing their dividend for me.

Dividend Income Summary: Lanny's July 2023 Summary

Chubb

Johnson Controls

Kimberly-Clark

Mondelez

Altria

July was exciting as ever as my year-over-year numbers continue to highlight the trifecta magic of dividend investing, which includes adding fresh capital, dividend raises and basic compounding to create an ever increasing passive income stream. I have to say I'm quite pleased with my July totals. Not too far from that coveted four-digit milestone too. After all, dividends don't lie. It's real cash being returned to investors. With patience and consistency these results and better can be achieved.

Dividend Income Update July 2023

Pfizer

British drugmaker GlaxoSmithKline is accusing Pfizer of infringing on four of its patents in its RSV vaccine.

Pfizer Sued By GSK Over Alleged Patent Infringement For Its RSV Vaccine

Both RSV vaccines were approved by the U.S. Food and Drug Administration for use in adults 60 and above.

GSK sues Pfizer in U.S. court for patent infringement over RSV vaccine

British biopharmaceutical giant GSK sued Pfizer in Delaware federal court on Wednesday, accusing Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo of violating GSK's patent rights in its rival RSV shot Arexvy.

GSK sues Pfizer in US for patent infringement over RSV vaccine

Darden Restaurants

General Motors

Intel

Restaurant Brands

Volkswagen AG

It's nice to own stocks that are well-positioned to rally and pay you for waiting for them to do so. That's especially true for older investors who want to buy stocks, and generate income.

If You Can Only Buy One Dividend Stock, It Better Be One of These 7 Names

ExScientia Ltd

The pharmaceutical sector generates a huge $1.2 trillion of revenue globally, and the U.S. is by far the most lucrative country for drug makers in the world. Therefore, the profits of successful American pharmaceutical firms can be truly staggering.

3 Millionaire-Maker Biotech Stocks to Buy Before the Window Closes

British drugmaker GSK has been in reorganization mode since 2017. The new GSK should sport higher growth, profitability, and increased productivity.

Is GSK Stock Worth Buying Right Now?

GSK's share price is down 15% on the 12-month chart, but its low valuation and decent earnings estimates present little downside risk for investors. Recent developments include the authorization of Arexvy by the Medicines and Healthcare Products Regulatory Agency and the acquisition of BELLUS Health, a biopharmaceutical company. Despite ongoing and expected lawsuits, GSK is seen as a good investment opportunity due to its strong margins, potential for growth through acquisitions, and a dividend yield of nearly 4%.

GSK: A Muted Valuation And Good Dividend Yield

GSK's revenues benefit from strong growth across all segments, especially HIV and vaccine. GSK raises guidance for earnings and sales.

GSK Beats on Q2 Earnings & Sales, Raises 2023 Guidance

London-based GSK is preparing to roll out its RSV vaccine in the U.S. and European Union this fall, when the disease begins to spread at higher levels.

GSK chief says RSV vaccine will start off slower than shingles shot – but will drive future sales

GSK plc (NYSE:GSK ) Q2 2023 Earnings Conference Call July 26, 2023 7:00 AM ET Company Participants Nick Stone - Senior Vice President, Head, Investor Relations Emma Walmsley - Chief Executive Officer Tony Wood - Chief Scientific Officer Luke Miels - Chief Commercial Officer Deborah Waterhouse - Chief Executive Officer, ViiV Healthcare & President, Global Health Julie Brown - Chief Financial Officer Conference Call Participants James Gordon - JPMorgan Jo Walton - Credit Suisse James Quigley - Morgan Stanley Emily Field - Barclays Peter Welford - Jeffries Eric Le Berrigaud - Stifel Michael Leuchten - UBS Graham Parry - Bank of America Rajesh Kumar - HSBC Richard Parkes - BNP Paribas Andrew Baum - Citi Kerry Holford - Berenberg Simon Baker - Redburn Emmanuel Papadakis - Deutsche Bank Steve Scala - Cowen Nick Stone Hello, everyone. Welcome to our Half Year End Q2 2023 conference call webcast investors and analysts.

GSK plc (GSK) Q2 2023 Earnings Call Transcript

GSK (GSK) came out with quarterly earnings of $0.97 per share, beating the Zacks Consensus Estimate of $0.85 per share. This compares to earnings of $0.87 per share a year ago.

GSK (GSK) Surpasses Q2 Earnings and Revenue Estimates

GlaxoSmithKline Pharmaceuticals , the Indian unit of UK's GSK plc , posted an 11% rise in first-quarter profit on Wednesday, buoyed by strong demand for its vaccines.

India's GlaxoSmithKline Pharma posts rise in Q1 profit on steady vaccine business

Pharmaceutical giant GSK beat expectations for the second quarter and raised its forecast for the full year.

Pharma Giant GSK Beats Second-Quarter Goals On Growth In Vaccines, General Medicines

GSK does not expect uptake of its RSV vaccine will initially be as swift as it was for its blockbuster shingles vaccine, though the company is confident in its new inoculation, Chief Executive Emma Walmsley said on Wednesday.

GSK expects RSV vaccine uptake will be slower than for its shingles vaccine-CEO

GSK PLC (LSE:GSK, NYSE:GSK) has upgraded its 2023 guidance following a strong second-quarter performance, driven by key growth drivers including its Shingrix vaccine for shingles. The pharmaceutical giant now expects turnover to increase by 8-10%, up from the previous estimate of 6-8%, and adjusted operating profit growth of 11-13%, up from 10-12%.

GSK upgrades forecasts as shingles vaccine continues to deliver

GSK raised its full-year profit and sales guidance on Wednesday after its second-quarter earnings beat expectations, helped by strong sales of its shingles vaccine Shingrix and HIV medicines.

GSK raises 2023 outlook boosted by vaccine, HIV drug sales

Lloyds Banking Group

Reckitt Benckiser Group PLC

British American Tobacco

Although Wednesday is Fed day, before that there's going to be a raft of news from big FTSE and Wall Street companies before the US central bank meets late in the day. Lloyds Banking Group PLC (LSE:LLOY) is chief among them, especially as it is among the lenders being tipped to pull in billions from what politicians have described as sharp practice: quickly hiking mortgage rates and slowly nudging up those for savings.

Lloyds, GSK, Reckitt and BAT results lead a busy Wednesday, plus Fed meeting

GSK Plc said on Monday that its HIV-focused unit ViiV Healthcare's cabotegravir injected drug and tablets got marketing authorisation from the European Medicines Agency.

GSK's HIV prevention drug gets European marketing nod

Amgen

Bristol-Myers

Pharma stocks experienced an abysmal first half due to various factors. Rotation from defensive to cyclical sectors, drug price negotiations and upcoming patent cliffs have muddied the outlook.

The 3 Most Undervalued Pharma Stocks to Buy Now: July 2023

GSK PLC (LSE:GSK, NYSE:GSK) shares have been trading near year's lows earlier this month, despite a run of fairly good news in the run-up to its quarterly update on Wednesday.  After hitting a decade low in 2021, the stock has had its ups and downs.

GSK trading near year lows in run-up to results, questions remain for Dame Emma

News for GlaxoSmithKline Stock (GSK)